Optipharm.CO.,LTD (KOSDAQ:153710)
4,300.00
-45.00 (-1.04%)
At close: Oct 23, 2026
Optipharm.CO.,LTD Revenue
Optipharm.CO.,LTD had revenue of 6.59B KRW in the quarter ending June 30, 2026, with 13.80% growth. This brings the company's total for the last twelve months to 23.59B, up 11.84% year-over-year. In the year 2025, Optipharm.CO.,LTD had annual revenue of 22.34B with 13.79% growth. That makes Optipharm.CO.,LTD the 34,446th largest company in the world by revenue and 2,206th in South Korea.
Revenue (ttm)
23.59B
Revenue Growth
+11.84%
P/S Ratio
2.67
Revenue / Employee
n/a
Employees
n/a
Market Cap
63.08B
Revenue by Segment
- Animal Medicine 10.11B 51.5%
- Animal Disease Diagnosis 5.53B 28.2%
- Bacteriophage 2.04B 10.4%
- Medipig 1.68B 8.6%
- Other 269.14M 1.4%
Fiscal year ended Dec 31, 2024 See the full Optipharm.CO.,LTD breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.34B | 2.71B | 13.79% |
| Dec 31, 2024 | 19.64B | 2.26B | 13.03% |
| Dec 31, 2023 | 17.37B | 1.36B | 8.52% |
| Dec 31, 2022 | 16.01B | 1.75B | 12.27% |
| Dec 31, 2021 | 14.26B | 1.21B | 9.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 269.63B |
| Daehan Nupharm | 211.48B |
| Sinsin Pharmaceutical | 123.05B |
| Hwail Pharmaceutical | 107.87B |
| Sinil Pharmaceutical | 86.82B |
| Sam-A Pharm. | 72.28B |
| Polaris AI Pharma | 63.94B |
| Samik Pharmaceutical Company LTD. | 62.26B |